The market sell-off continued, showing signs of spreading beyond the tech sector. One culprit was oil. Increasing tensions in the Middle East lifted Brent crude oil to a six-month high of around $116 a barrel. U.S. oil prices climbed back above the psychologically important $100-per-barrel mark. Th....
Good MorningU.S. stocks came under pressure Friday, with the Dow falling sharply and the Nasdaq giving back earlier gains as investors continued to weigh concerns about technology shares. Worries about a potential AI-driven cyclical downturn remained in focus, while Meta faced a steep weekly decline. Still, forecasts for AI infrastructure remain sizable, with Bank of America estimating global data-center spending could more than double to $2.1 trillion by 2028.
Corporate earnings drove divergent moves. Tesla shares edged lower as tariff refunds clouded an apparent margin beat, while Autoliv fell after missing third-quarter sales and adjusted EPS expectations. Comfort Systems also declined despite reporting revenue and earnings beats and a growing backlog. American Express said it plans to cut about 5% of its global workforce as it seeks greater efficiency and expands AI use, while spending among its Gen Z cardholders rose 35% year over year.
Energy shares advanced Friday, supported by higher oil prices. Targa Resources gained about 4%, while Transocean remained in focus following new offshore drilling contracts that increased its backlog. Crown Castle jumped about 12% on reports of a potential SpaceX tower deal, while Newmont's quarterly results beat estimates as higher gold prices lifted sales. Featured: Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) 
|
Technology |
|
The market sell-off continued, showing signs of spreading beyond the tech sector. One culprit was oil. Increasing tensions in the Middle East lifted Brent crude oil to a six-month high of around $116 a barrel. U.S. oil prices climbed back above the psychologically important $100-per-barrel mark. Th... Read the Full Story |
|
|
|
Communication Services |
|
Shares of Spotify Technology (NYSE: SPOT) surged following the company’s latest earnings report, ending its two-quarter streak of post-earnings falls. Spotify shares gained 11%, good for the entertainment stock’s largest single-day gain since May, and leaving shares roughly flat on the year. In co... Read the Full Story |
|
Industrials |
|
Lockheed Martin (NYSE: LMT) reported third-quarter results on Thursday, Oct. 22, and on paper, there was little to complain about. Earnings came in at $7.97 per share, well ahead of the $7.52 analysts expected, while revenue climbed 11.3% over the prior year to $20.7 billion. Management also raised... Read the Full Story |
|
From Our Partners |
|
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors.
Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. |
| Read Tilson's free analysis and find out what to do with your money |
|
Technology |
|
Palantir Technologies (NASDAQ: PLTR) has been revalued since its Q2 2026 earnings report. The share price is up over 55% since the report, which has set a higher floor. But investors are wondering about the ceiling. Valuation concerns still make investors wary of overpaying, even as the company kee... Read the Full Story |
|
Energy |
|
Kinder Morgan (NYSE: KMI) is a growing company with highly visible revenue and cash flow. While visibility can hinder stock price action by enabling the market to accurately price in the outlook, Kinder Morgan’s trends are bullish—this market is perpetually catching up with an improving outlook. Ke... Read the Full Story |
|
|
|
Finance |
|
Capital One Financial Corp. (NYSE: COF) delivered a solid Q3 2026 earnings report. Adjusted earnings per share (EPS) were $6.69, up 12% from $5.95 a year earlier. Revenue rose 6% year over year to $16.3 billion. The stock got a lift of about 4% the morning after the report was released on Oct. 20.... Read the Full Story |
|
Consumer Discretionary |
|
Tractor Supply Company’s (NASDAQ: TSCO) share price imploded over the past year, falling more than 50% from its 2025 highs to its October 2026 lows, but signs of a potential turnaround are emerging. The company struggled with factors inside and outside its control, and now some are beginning to ali... Read the Full Story |
|
Consumer Staples |
|
WD-40 Company (NASDAQ: WDFC) isn't a headline-making company or a hypergrowth story, and its stock is likely to remain range-bound. But it also presents an attractive opportunity for investors seeking compounding returns. Trading near the low end of its range, this dividend-paying, share-buying ma... Read the Full Story |
|
Utilities |
|
Approved by shareholders on Sept. 3, 2026, NextEra’s (NYSE: NEE) proposed merger with Dominion Energy (NYSE: D) would create the world's largest regulated utility business by market capitalization and potentially support long-term dividend growth. At face value, the deal combines NextEra’s power-ge... Read the Full Story |
|
Technology |
|
Microsoft Corp. (NASDAQ: MSFT) heads into its Q1 report for fiscal year 2027 (FY2027) with very little room for error. The stock closed at over $530 per share on Oct. 21; that's within striking distance of its 52-week high of $553.72. MSFT is up about 33% since the company last reported earnings, ... Read the Full Story |
|
The Early Bird Stock Of The Day Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finis... |
Should I Buy Danaher Stock? DHR Bull and Bear Case ExplainedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Danaher was last updated on Wednesday, October 21, 2026 at 6:37 PM. Danaher Bull Case
- Danaher Co. recently reported third-quarter 2026 earnings that significantly exceeded expectations, with adjusted diluted earnings per share of $2.11, which beat the consensus estimate of $1.92 by approximately 9.9%, demonstrating strong profitability and operational execution.
- The company raised its full-year 2026 adjusted earnings per share guidance to a range of $8.57 to $8.62, signaling management confidence in sustained growth and improved market conditions across its Biotechnology, Life Sciences, and Diagnostics segments.
- Core revenue growth excluding respiratory testing accelerated to 5.5% in the third quarter, up 100 basis points from the second quarter, indicating a robust recovery in demand and effective commercial execution despite headwinds in specific product lines.
- Danaher Co. generated $1.6 billion in free cash flow during the third quarter and $4 billion through the first nine months of the year, providing substantial liquidity for disciplined capital allocation, share buybacks, or further strategic investments.
- The stock is currently trading at $233.99, which is near its 52-week high of $242.80, reflecting strong investor sentiment and a significant recovery from its 52-week low of $160.93, suggesting momentum and market confidence in the company's new strategic direction.
Danaher Bear Case
- Respiratory testing revenue created an approximately 250-basis-point headwind to core revenue growth in the third quarter, resulting in reported core revenue growth of only 3%, highlighting continued vulnerability and declining demand in this specific diagnostic area.
- The company's price-to-earnings ratio stands at 41.56, which is relatively high and may limit upside potential if future earnings growth does not accelerate to justify the premium valuation, especially compared to historical averages.
- Short interest increased by 7.49% in the most recent reporting period to 8,969,401 shares, indicating that a growing number of investors are betting against the stock, which could signal underlying concerns about the company's future performance or valuation.
- Recent insider trading activity includes multiple sales by executives, such as Gregory M. Milosevich selling 1,320 shares in February 2026 and Brian W. Ellis selling 21,776 shares in November 2025, which may suggest that insiders are taking profits or have less confidence in near-term stock appreciation.
- The company is undergoing a leadership transition with Julie Sawyer Montgomery as the new CEO, and while she has outlined strategic priorities, the market may be uncertain about the execution of her plan to become the "defining leader in Life Sciences and Diagnostics," creating potential volatility and risk.
|
| View Today's Stock Pick |
|
|
|
No comments:
Post a Comment